WO2007009700A2

WO2007009700A2 - Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome

Info

Publication number: WO2007009700A2
Application number: PCT/EP2006/006974
Authority: WO
Inventors: Helmut H. Buscmann
Original assignee: Laboratorios Del Dr. Esteve, S.A.
Priority date: 2005-07-15
Filing date: 2006-07-15
Publication date: 2007-01-25
Also published as: ES2326857A1; WO2007009700A3; ES2326857B1

Abstract

The present invention relates to the use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome in humans and animals.

Description

Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome

The present invention relates to the use of substituted pyrazoline compounds for the treatment of metabolic syndrome, especially the lipid parameters of the metabolic syndrome in humans and animals.

The metabolic syndrome is a widespread disease, particularly in the United States and Europe. Based on survey data from 1988 to 1994 and 2000 census data, the American Center for Disease Control and Prevention estimates that 47 million people in the US have metabolic syndrom. Thus, there is an urgent need for effective therapy of the metabolic syndrome.

Consequently, it was an object of the present invention to provide medicaments, which are suitable for the treatment of metabolic syndrome.

Said object was achieved by using the substituted pyrazoline compounds of general formula I given below, their stereoisomers, corresponding salts and corresponding solvates thereof.

It has been found that these compounds have a marked effect on parameters, especially on the lipid parameters, related to the metabolic syndrome.

Thus, in one of its aspects the present invention relates to the use of a substituted pyrazoline compounds of general formula I

wherein

R¹ represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group,

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C-i-e-alkyl group, a linear or branched d-₆-alkoxy group, a halogen atom, CH₂F₁ CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched Ci-β alkyl,

R⁵ and R⁶ independently of each other represent a linear or branched Ci-₆- alkyl group, a linear or branched Ci-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN₁ OH₁ NO₂, -(C=O)-R¹⁰. SH₁ SR¹⁰, SOR¹⁰, NH₂. NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂. -(C=O)-NHR¹⁰ and -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C₁-₆ alkyl; R⁷ represents hydrogen, a linear or branched

group, a linear or branched Ci-e-alkoxy group, a halogen atom, CH₂F₁ CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH₁ SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)- NHR¹⁰ and -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C1-6 alkyl;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof,

for the manufacture of a medicament for the treatment of metabolic syndrome, especially influencing the blood and lipid parameters related to the metabolic syndrome.

These compounds had a surprising effect on blood parameters, especially the lipid parameters of the metabolic syndrome.

Preferably as a proviso (disclaimer) these lipid parameters do not include triglyceride levels.

As defined here treatment does also include prophylaxis.

The metabolic syndrome and definitions thereof are described in detail by Eckel et al., The Lancet, Vol. 365 (2005), 1415-1428, included herewith by reference. One of the respective definitions was established by the WHO in 1998 (as described in Alberti et al., Diabet. Med. 1998, 15, pages 539-53, the respective description thereof is herewith incorporated by reference and forms part of the present disclosure). The other, more widely accepted, definition of the metabolic syndrome was established by the Adult Treatment Panel (ATP III) of the US National Cholesterol Education Program (NCEP) in 2001, as described in JAMA 2001; 285; 2486-97, the respective description thereof is herewith incorporated by reference and forms part of the present disclosure. The metabolic syndrome is characterized by an interaction of several physiological parameters such as triglycerides, lipids, blood pressure, glucose levels and insuline levels.

Even though obesity may play a critical role in the development of metabolic syndrome, many of its aspects are weight independent, especially some lipid parameters. Especially the positive influence on the weight independent aspects of the metabolic syndrome (see e.g. Pagotto and Pasquali, The Lancet, Vol. 365 (2005), 1363, 1364, included herewith by reference) like some blood parameters, especially lipid parameters is one of the major and surprising advantages of the inventively used substituted pyrazoline compounds.

Especially the positive influence on the weight independent aspects of the metabolic syndrome like some blood parameters, especially lipid parameters is one of the major and surprising advantages of the compounds according to general formula I, II, and their combination with a compound according to general formula X.

Since the pyrazoline compounds as defined herein also have a beneficial effect on the ratio of low density lipoprotein (LDL) to high density lipoprotein (HDL)₁ i.e. they lower the LDL-levels and/or elevate the HDL levels; they are also useful as coating material or co-coating material in stents in order to prevent restenosis.

In addition the inventively used pyrazoline compounds seem to be distinguished by a broad spectrum of beneficial effects, while at the same time showing relatively little undesired effects, i.e. effects which do not positively contribute to or even interfere with the well being of the patient.

In another aspect the present invention relates to the use of a substituted pyrazoline compounds of general formula I

wherein

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched d-β-alkyl group, a linear or branched Ci-6-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH₁ NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, SO₂R⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ Or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched C1-₆ alkyl,

R⁵ and R⁶ independently of each other represent a linear or branched Chalky! group, a linear or branched d-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ and -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C_1-6 alkyl; R⁷ represents hydrogen, a linear or branched Ci-6-alkyl group, a linear or branched Ci-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)- NHR¹⁰ and -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each s substituent independently represent linear or branched Ci_-6 alkyl;

optionally in form of one oϊ the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing o ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof,

for the manufacture of a medicament for the treatment of the lipid parameters of the metabolic syndrome. 5

In a preferred embodiment if for these compounds according to formula I the 0 following proviso (disclaimer) applies: neither of R², R³ or R⁴ may represent SO₂R⁸ in para-position with R⁸ being methyl.

5 Preferred linear or branched, saturated or unsaturated aliphatic groups, which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethinyl, propenyl, propinyl, butenyl and butinyl. 0

In the context of this invention, alkyl and cycloalkyl radicals are understood as meaning saturated and unsaturated (but not aromatic), branched, unbranched and cyclic hydrocarbons, which can be unsubstituted or mono- or polysubstituted. In these radicals, Ci_-2-alkyl represents C1- or C2-alkyl, Ci-3-alkyl represents C1-, C2- or C3-alkyl, d-4-alkyl represents C1-, C2-, C3- or C4-alkyl, Ci_-5-alkyl represents C1-, C2-, C3-, C4-, or C5-alkyl, C^-alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl, Ci-7-alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl, d-β-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or C8-alkyl, Ci.io-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9- or C10-alkyl and Ci_-18-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11-, C12-, C13-, C14-, C15-, C16-, C17- or C18-alkyl. Furthermore, C_3-4-cycloalkyl represents C3- or C4-cycloalkyl, C₃.₅- cycloalkyl represents C3-, C4- or Cδ-cycloalkyl, C_3-6-cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl, C_3-7-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl, C₃-₈-cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl, C_4-5-cycloalkyl represents C4- or C5-cycloalkyl, C₄-₆-cycloalkyl represents C4-, C5- or C6-cycloalkyl, C_4-7-cycloalkyl represents C4-, C5-, C6- or CT-cycloalkyl, C_5-6-cycloalkyl represents C5- or C6-cycloalkyl and C_5-7-cycloalkyl represents C5-, C6- or C7-cycloalkyl. In respect of cycloalkyl, the term also includes saturated cycloalkyls in which one or 2 carbon atoms are replaced by a heteroatom, S, N or O. However, mono- or polyunsaturated, preferably monounsaturated, cycloalkyls without a heteroatom in the ring also in particular fall under the term cycloalkyl as long as the cycloalkyl is not an aromatic system. The alkyl and cycloalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propinyl, methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 1,2- dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1 -methyl pentyl, cyclopropyl, 2- methylcyclopropyl, cyclopropyl methyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl, (if substituted also CHF2, CF₃ or CH₂OH) as well as pyrazolinone, oxopyrazolinone, [1 ,4]-dioxane or dioxolane.

Here, in connection with alkyl and cycloalkyl - unless expressly defined otherwise - the term substituted in the context of this invention is understood as meaning replacement of at least one hydrogen radical by F, Cl, Br, I, NH₂, SH or OH, "polysubstituted" radicals being understood as meaning that the replacement takes effect both on different and on the same atoms several times with the same or different substituents, for example three times on the same C atom, as in the case of CF₃, or at different places, as in the case of -CH(OH)-CH=CH-CHCI₂. Particularly preferred substituents here are F, Cl and OH. In respect of cycloalkyl, the hydrogen radical can also be replaced by OCi.₃-alkyl or Ci_-3-alkyl (in each case mono- or polysubstituted or unsubstituted), in particular methyl, ethyl, n-propyl, i-propyl, CF₃, methoxy or ethoxy.

The term (CH₂)₃-β is to be understood as meaning -CH2-CH2-CH2-, -CH₂-CH₂-CH₂- CH₂-, -CH₂-CH₂-CH₂-CH₂-CH₂- and -CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-, (CH₂)^ is to be understood as meaning -CH₂-, -CH₂-CH₂-, -CH₂-CH₂-CH₂- and -CH₂-CH₂-CH₂-CH₂-, (CH₂)₄-₅ is to be understood as meaning -CH₂-CH₂-CH₂-CH₂- and -CH₂-CH₂-CH₂- CH₂-CH₂-, etc.

An aryl radical is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or monosubstituted or polysubstituted.

A heteroaryl radical is understood as meaning heterocyclic ring systems which have at least one unsaturated ring and can contain one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur and can also be mono- or polysubstituted. Examples which may be mentioned from the group of heteroaryls are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline.

Here, in connection with aryl and heteroaryl, substituted is understood as meaning substitution of the aryl or heteroaryl by R, OR, a halogen, preferably F and/or Cl, a CF₃, a CN, an NO₂, an NRR, a Ci-₆-alkyl (saturated), a Ci-e-alkoxy, a C_3-8- cycloalkoxy, a C₃-₈-cycloalkyl or a C_2-6-alkylene.

The term "salt" is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes which are complexed via ionic interactions. It especially includes physiologically acceptable salts, which is to be used equivalents to pharmacologically acceptable salts.

The term "physiologically acceptable salt" means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic- especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.

These physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals. The salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH4, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.

These physiologically acceptable salts can also be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually protonated, for example on the nitrogen - as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals. By this is understood in particular, in the context of this invention, the salt formed with a physiologically tolerated acid, that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.

The term "solvate" according to this invention is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate. Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbon or ¹⁵N-enriched nitrogen are within the scope of this invention.

The invention also covers the use of any prodrug of the compounds described for the invention. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard- Larsen et al., Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002).

In a preferred embodiment of the invention the compound according to general formula I is selected from compounds according to general formula Ia or Ib or any mixture thereof

Ia Ib

In a preferred embodiment of the invention for a compound according to formula I at least one of R², R³ or R⁴ represents hydrogen, while at least one of R², R³ or R⁴ is different from hydrogen. In a preferred embodiment of the invention for a compound according to formula I R⁷ represents hydrogen.

In a preferred embodiment of the invention for a compound according to formula I R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched Ci_-6- alkyl group, a halogen atom, or CF₃, preferably R², R³ and R⁴ independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF₃.

In a preferred embodiment of the invention for a compound according to formula I R⁵ and R⁶ independently of each other represent a linear or branched Ci-6-alkyl group, a halogen atom, or CF₃, preferably R⁵ and R⁶ independently of each other represent methyl, ethyl, F₁ Cl, Br and CF₃.

In a preferred embodiment of the invention for a compound according to formula I R² represents a chlorine atom in the 4-position of the phenyl ring, while R³ and R⁴ represent hydrogen.

In a preferred embodiment of the invention for a compound according to formula I R⁵ and R⁶ each represent a chlorine atoms in the 2- and 4-position of the phenyl ring, while R⁷ represents hydrogen.

In a preferred embodiment of the invention for a compound according to formula I R¹ represents hydrogen, methyl or ethyl, preferably hydrogen.

In a highly preferred further aspect of the invention the compound of general formula I is represented by a compound of general formula Il

II

wherein

R¹² or R¹³ independently of each other represent a linear or branched d-β- alkyl group, a linear or branched Ci-₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH₁ NH₂, hydrogen, methyl, ethyl, F₁ Cl, Br and CF₃,

R¹⁴ or R¹⁵ independently of each other represent a linear or branched C1-₆- alkyl group, a linear or branched Ci-₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, methyl, ethyl, F, Cl, Br and CF₃,

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof.

12 In a preferred embodiment of the invention the compound according to general formula Il is selected from compounds according to general formula Ha or lib or any mixture thereof

Ha lib

In a preferred embodiment of the invention for a compound according to formula Il R¹² and R¹³ independently of each other represent hydrogen, a linear or branched CV ₆-alkyl group, a halogen atom, or CF₃, preferably R¹² and R¹³ independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF₃.

In a preferred embodiment of the invention for a compound according to formula Il R¹⁴, and R¹⁵ independently of each other represent a linear or branched d-β-alkyl group, a halogen atom, or CF₃, preferably R¹⁴ and R¹⁵ independently of each other represent methyl, ethyl, F₁ Cl₁ Br and CF₃.

In a preferred embodiment of the invention for a compound according to formula Il

R »13 represents Cl and R 12 represents hydrogen.

In a preferred embodiment of the invention for a compound according to formula R¹⁴ and R¹⁵ each represent Cl. In a preferred embodiment of the invention for a compound according to formula Il R¹ represents hydrogen, methyl or ethyl, preferably hydrogen.

In another preferred embodiment the compound according to formula I or Il is selected from the group consisting of:

• 5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3- carboxylic acid,

• (rac)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1 H-pyrazol- 3-carboxylic acid,

• (R)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4.5-d'hydro-1H-pyrazol- 3-carboxylic acid,

• (S)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol- 3-carboxylic acid,

or any mixture thereof

optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

In a preferred embodiment of the invention for the manufacture of the medicament in addition to at least one compound according to either of general formulas I, Ia, Ib, II, Ha and/or Mb at least one substituted pyrazoline compound according to general formula X is being used, with

wherein

R¹⁶ represents an optionally at least mono-substituted phenyl group,

R¹⁷ represents an optionally at least mono-substituted phenyl group,

R¹⁸ represents a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an -

NR¹⁹R²°-moiety,

R¹⁹ and R²⁰, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group, an -SO₂-R²¹-moiety, or an - NR²²R²³-moiety, with the proviso that R¹⁹ and R²⁰ do not identically represent hydrogen, R²¹ represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

R²² and R²³, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

In a preferred embodiment of the invention in the compound according to general formula X R¹⁶ represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched d-₆-alkyl group, a linear or branched d-β-alkoxy group, a halogen atom, CH₂F₁ CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R', SH, SR', SOR', SO₂R', NH₂, NHR', NR'R", -(C=O)-NH₂, -(C=O)-NHR' and -(C=O)-NR¹R" whereby R' and R" for each substituent independently represent linear or branched Ci_-6 alkyl, preferably R¹⁶ represents a phenyl group, which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF₃, more preferably R¹⁶ represents a phenyl group, which is mono-substituted with a chlorine atom in the 4-position.

In a preferred embodiment of the invention in the compound according to general formula X R¹⁷ represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched

group, a linear or branched Ci-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R', SH, SR', SOR', SO₂R', NH₂, NHR', NR¹R", -(C=O)-NH₂, -(C=O)-NHR' and -(C=O)-NR¹R", whereby R' and optionally R" for each substituent independently represent linear or branched Ci_-6 alkyl, preferably R¹⁷ represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF₃, more preferably R¹⁷ represents a phenyl group, which is di-substituted with two chlorine atoms in its 2- and 4-position.

In a preferred embodiment of the invention in the compound according to general formula X R¹⁸ represents a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C_3-8 cycloaliphatic group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, or an optionally at least mono- substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an - NR¹⁹R²°-moiety, preferably R¹⁸ represents a saturated, optionally at least mono- substituted, optionally one or more nitrogen-atoms as ring member containing C₃^ cycloaliphatic group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, or an -NR¹⁹R²°-moiety, more preferably R¹⁸ represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, whereby each of these groups may be substituted with one or more Ci-₆-alkyl groups, or an -NR¹⁸R¹⁹-moiety.

In a preferred embodiment of the invention in the compound according to general formula X R¹⁹ and R²⁰, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono- substituted d-₆-aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C₃-₈- cycloaliphatic group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, or an optionally at least mono- substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene (-CH2-) or ethylene (-CH₂-CH₂)-group, an -SO2-R²¹ -moiety, or an -NR²²R²³-moiety, preferably one of these residues R¹⁹ and R²⁰ represents a hydrogen atom and the other one of these residues R¹⁹ and R²⁰ represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C^-e-cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, an -Sθ₂-R²¹-moiety, or an -NR²²R²³- moiety, or R¹⁹ and R²⁰, identical or different, each represent a C1-₆ alkyl group, more preferably one of these residues R¹⁹ and R²⁰ represents a hydrogen atom and the other one of these residues R¹⁹ and R²⁰ represents an optionally at least mono- substituted pyrrolidinyl group, an optionally at least mono-substituted piperidinyl group, an optionally at least mono-substituted piperazinyl group, an optionally at least mono-substituted triazolyl group, an -Sθ2-R²¹-moiety, or an -NR²²R²³-moiety, or R¹⁹ and R²⁰, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tert.-butyl group.

In a preferred embodiment of the invention in the compound according to general formula X R²¹ represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C_1-6 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C₃-₈ cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a methylene (-CH₂-) or ethylene (-CH2-CH₂)-group, preferably R²¹ represents a C-ι-₆-alkyl group, a saturated, optionally at least mono-substituted cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-

is system, or a phenyl group, which is optionally substituted with one or more Ci_-6 alkyl groups.

In a preferred embodiment of the invention in the compound according to general formula X R²² and R²³, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono- substituted Ci-6 aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3-8 cycloaliphatic group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, or an optionally at least mono- substituted, 5- or 6 membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene (-CH₂-) or ethylene (-CH₂-CH₂)-group, preferably R²² and R²³, identical or different, represent a hydrogen atom or a Ci-β alkyl radical.

In a preferred embodiment of the invention the compound according to general formula X is represented by a structure wherein

R¹⁶ represents a phenyl ring, which is mono-substituted with a halogen atom, preferably a chlorine atom, in its 4-position,

R¹⁷ represents a phenyl ring, which is di-substituted with two halogen atoms, preferably chlorine atoms, in its 2- and 4-position,

R¹⁸ represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, or an -NR¹⁹R²⁰-moiety,

R¹⁹ represents a hydrogen atom or a linear or branched Ci_6-alkyl group,

R²⁰ represents a linear or branched Ci_-6 alkyl group, an -SO₂-R²¹-moiety, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, whereby each of the heterocyclic rings may be substituted with one or more, identical or different, CWalkyl groups, and R²¹ represents a phenyl group, which is optionally substituted with one or more C1-₆ alkyl groups, which may be identical or different,

In a preferred embodiment of the invention at least one compound according to formula X is selected from the group consisting of:

(rac)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazol-3-carboxamide,

(S)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazol-3-carboxamide,

(R)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazol-3-carboxam ide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid-[1 ,2,4]-triazole-4-yl-amide_I

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid-(4-methyl-piperazin-1-yl)-amide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid diethylamide,

[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-yl]- piperidine-1-yl-methanone, N-Iδ-C^Chloro-phenyO-i^.^dichlorophenylH.δ-dihydro-IH-pyrazole-S- carbonyl]-4-m ethyl phenyl sulfonamide,

In a preferred embodiment of the use according to the invention at least the following compounds are used:

• δ-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,δ-dihydro-1 H-pyrazol-3- carboxylic acid,

• (rac)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4.5-dihydro-1H-pyrazol- 3-carboxylic acid,

• (RJ-δ^chloro-phenyO-I^AdichlorophenylH.δ-dihydro-IH-pyrazol- 3-carboxylic acid,

• (SJ-δ-^chloro-phenyO-i-^Adichlorophenyl^.δ-dihydro-IH-pyrazol- 3-carboxylic acid,

or any mixture thereof

and

• N-piperidinyl-δ-^chloro-phenyO-i-^.ΦdichlorophenyO^.δ-dihydro-IH^ pyrazol-3-carboxamide;

• (rac)-N-piperidinyl-δ-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,δ- dihydro-1 H-pyrazol-3-carboxamide;

• (RJ-N-piperidinyl-δ-CΦchloro-phenyO-I^AdichlorophenylH.δ-dihydro- 1 H-pyrazol-3-carboxamide; • (S)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4_I5-dihydro-

1 H-pyrazol-3-carboxamide; or any mixture thereof

each optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

Another aspect of the invention is the use of one or more pyrazoline compounds or mixtures as defined herein for the manufacture of a medicament for improvent of cardiovascular and/or metabolic risk factors, such as one or more of the following factors:

Elevated triglycerides, whereby elevated levels of triglycerides are preferably understood as being > 150 mg/dl,

Low HDL cholesterol, whereby low levels of HDL cholesterol are preferably understood as being < 40 mg/dl in men and < 50 mg/dl in women,

Hypertension, whereby hypertension is preferably understood as being > 130/85 mmHg,

Impaired fasting glucose, whereby impaired fasting glucose levels are preferably understood as being > 110 mg/dl,

Insulin resistance

Dyslipidemia.

Another aspect of the invention is the use of one or more pyrazoline compounds or mixtures as defined herein for the manufacture of a medicament for the treatment of the weight independent aspects of metabolic syndrome.

Another aspect of the invention is a method for improving cardiovascular and/or metabolic risk factors, such as one or more of the following factors: Elevated triglycerides, whereby elevated levels of triglycerides are preferably understood as being > 150 mg/dl,

Insulin resistance

Dyslipidemia,

in a subject, preferably a human.

Another aspect of the invention is a method for treating of the weight independent aspects of metabolic syndrome.

The inventively used substituted pyrazoline compounds of general formula (I) given above, their stereoisomers, corresponding N-oxides, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.

Another aspect of the invention is the use of the compounds according to general formula I or Il or their combination with compounds of general formula X for the manufacture of a medicament for the treatment of cardiovascular risk factors caused by metabolic/food disorders, especially a combination of consequences of these disorders.

Another aspect of the invention is the use of the compounds according to general formula I or Il or their combination with compounds of general formula X for the manufacture of a medicament for the treatment of the metabolic syndrome, especially of its weight independent aspects, preferably with the proviso (disclaimer) to exclude Triglyceride levels.

The process to acquire compounds according to general formula I is illustrated in scheme I given below:

Scheme I:

The reaction of the benzaldehyde compound of general formula III with a pyruvate compound of general formula IV is preferably carried out in the presence of at least one base, more preferably in the presence of an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide or an alkali metal methoxide such as sodium methoxide, as described, for example, in Synthetic communications, 26(11), 2229-33, (1996). The respective description is hereby incorporated by reference and forms part of the disclosure. Preferably said reaction is carried out in a protic reaction medium such as a Ci_-4 alkyl alcohol or mixtures of these.

Reaction temperature as well as the duration of the reaction may vary over a broad range. Preferred reaction temperatures range from -10 ⁰C to the boiling point of the reaction medium. Suitable reaction times may vary for example from several minutes to several hours.

The reaction of the benzaldehyde compound of general formula III with a pyruvate compound of general formula IV is preferably carried out under acid catalysed conditions, more preferably by refluxing the mixture in dichloromethane in the presence of copper(ll)trifluoromethanesulfonate as described, for example, in Synlett, (1), 147-149, 2001. The respective description is hereby incorporated by reference and forms part of the disclosure.

The reaction of the compound of general formula (V) with an optionally substituted phenyl hydrazin of general formula (Vl) is preferably carried out in a suitable reaction medium such as d-4-alcohols or ethers such as dioxane or tetrahydrofurane or mixtures of at least two of these afore mentioned compounds. Also preferably, said reaction may be carried out in the presence of an acid, whereby the acid may be organic such as acetic acid and/or inorganic such as hydrochloric acid. Furthermore, the reaction may also be carried out in the presence of a base such as piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, or a mixture of at least two of these bases may also be used.

Reaction temperature as well as the duration of the reaction may vary over a broad range. Suitable reaction temperatures range from room temperature, i.e. approximately 25 ⁰C to the boiling point of the reaction medium. Suitable reaction times may vary for example from several minutes to several hours.

The carboxylic group of the compound of general formula (VII) may be activated for further reactions by the introduction of a suitable leaving group according to conventional methods well known to those skilled in the art, leading to a compound according to general formula (Vila).

Preferably the compounds of general formula (VII) are transferred into an acid chloride, an acid anhydride, a mixed anhydride, a Ci_-4 alkyl ester, an activated ester such as p-nitrophenylester. Other well known methods for the activation of acids include the activation with N,N-dicyclohexylcarbodiimide or benzotriazol-N- oxotris(dimethylamino) phosphonium hexafluorophosphate (BOP)).

If said activated compound of general formula (Vila) is an acid chloride, it is preferably prepared by reaction of the corresponding acid of general formula (VII) with thionyl chloride or oxalyl chloride, whereby said chlorinating agent is also used as the solvent. Also preferably an additional solvent may be used. Suitable solvents include hydrocarbons such as benzene, toluene or xylene, halogenated hydrocarbons such as dichloromethane, chloroform or carbon tetrachloride, ethers such as diethyl ether, dioxane, tetrahydrofurane or dimethoxyethane. Mixtures of two or more solvents from one class or two or more solvents from different classes may also be used. Preferred reaction temperature range from 0° C to the boiling point of the solvent and reaction times from several minutes to several hours.

If said activated compound of general formula (Vila) is a mixed anhydride, said anhydride may preferably be prepared, for example, by reaction of the corresponding acid of general formula (Vila) with ethyl chloroformiate in the presence of a base such as triethylamine or pyridine, in a suitable solvent.

Following that the activated compound can be reacted with an alkyl-alcohol to arrive at compounds according to general formulas I or Il with R¹ being a a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci-4-alkyl group.

In addition, as A represented in general formula Vila represents a leaving group, via the reaction with an activating agent, said compound being optionally isolated and/or optionally purified, and at least one compound of general formula (Vila) is reacted with a compound of general formula R¹⁸H, wherein R¹⁸ represents an -NR¹⁹R²⁰- moiety, wherein R¹⁹ and R²⁰ have the meaning given above for compounds of general formula X₁ to yield a substituted pyrazoline compound of general formula X, wherein R¹⁸ represents an -NR¹⁹R²⁰-moiety, During the processes described above the protection of sensitive groups or of reagents may be necessary and/or desirable. The introduction of conventional protective groups as well as their removal may be performed by methods well-known to those skilled in the art.

If the substituted pyrazoline compounds of general formula I or Il themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractionalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis, especially using chiral bases like brucine, quinine, (-)- Cinchonidine, (+)-Cinchonine or R-(+)-1-Phenylethylamine.

In a process for the preparation of salts of substituted pyrazoline compounds of general formula I or Il and stereoisomers thereof, at least one compound of general formula I or Il having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.

In a process for the preparation of salts of substituted pyrazoline compounds of general formula I or Il or stereoisomers thereof, at least one compound of general formula I or Il having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. [NH_nR4-n]⁺, wherein n is 0, 1, 2, 3 or 4 and R represents a branched or unbranched Ci-4-alkyl-radical. Suitable reaction media are, for example, any of the ones given above. Solvates, preferably hydrates, of the substituted pyrazoline compounds of general formula I or II, of corresponding stereoisomers, of corresponding N-oxides or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.

Substituted pyrazoline compounds of general formula I or II, which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.

The purification and isolation of the substituted pyrazoline compounds of general formula I or II, of a corresponding stereoisomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.

The substituted pyrazoline compounds of general formula I, Ia, Ib, II, Ha, lib and X given below, their corresponding N-oxides, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances.

The medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art. The composition of the medicament may vary depending on the route of administration.

The medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols. Conventional pharmaceutical excipients for injection, such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions. These medicaments may for example be injected intramuscularly, intraperitoneal Iy, or intravenously. Solid oral compositions (which are preferred as are liquid ones) may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to the methods well known in normal pharmaceutical practice., in particular with an enteric coating.

The mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopeias and similar reference texts.

Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents. The compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.

The liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents. Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.

The compositions of the present invention may also be administered topically or via a suppository.

The daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth. The daily dosage for humans may preferably be in the range fromi to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.

Another aspect of the present invention relates to an active substance combination comprising as component (A) one or more of the substituted pyrazoline compounds as defined herein and as component (B) an agent selected from the group consisting of antihyertensive agents, agents for treating insuline resistance and agents for treating dyslipidemia.

Suitable antihyertensive agents, agents for treating insuline resistance and agents for treating dyslipidemia as well as their dosages are well known to those skilled in the art.

Antihyertensive agents may preferably be selected from the group consisting of Hydrochlorothiazide, Furosemide, Triamterene.Triamterene/hydrochlorothiazide, Spironolactone, Eplerenone, Amlodipine, Nifedipine, Diltiazem, Verapamil, Atorvastatin/amlodipine, Enalapril, Lisinopril, Ramipril, Lisinopril/hydrochlorothiazide, Benazepril/amlodipine, Losartan, Valsartan, Irbesartan, Candesartan cilexetil, Olmesartan, Losartan/hydrochlorothiazide, Valsartan/hydrochlorothiazide, HCT/CoDiovan/Cotareg, Atenolol, Metoprolol tartrate, Metoprolol succinate and Carvedilol. Agents for treating insuline resistance may preferably be selected from the group consisting of Metformin, Metformin extended release, Pioglitazone, Rosiglitazone and Metformin/rosiglitazone. Agents for treating dyslipidemia may preferably be selected from the group consisting of Colesevelam, Cholestyramine, Clofibrate, Fenofibrate, Fulcro/Secalip, Bezafibrate, Gemfibrozil, Ciprofibrate, Niacin, Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin, Ezetimibe, Lovastatin/niacin, Atorvastatin/amlodipine and Simvastatin/ezetimibe.

Another aspect of the present invention is method of treating metabolic syndrome comprising administering to a subject, preferably a human, a therapeutically effective amount of at least one substituted pyrazoline compound, or mixtures, as defined herein. The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and are not intended to limit the present invention.

Examples:

Example 0 represent a compound according to formula I or II.

Example 0:

5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid

a) 4-(4-chlorophenyl)-2-oxo-3-butenoic acid

In a three neck flask p-chlorobenzaldehyde (13,3 g, 95 mmoles) and ethyl pyruvate (10 g, 86 mmoles) were dissolved in 150 ml of absolute ethanol.The solution was ice- cooled to 0⁰C and an aqueous solution of NaOH (3.8 g in 45 ml_ water) was added dropwise keeping the temperature below or equal to 10⁰C, whereby a yellow-orange colored precipitate was formed. The reaction mixture was stirred for 1 hour at 0⁰C and an additional 1.5 hours at room temperature (approximately 25 ⁰C). Afterwards the reaction mixture was cooled down to approximately 5°C and the insoluble sodium salt of 4-(4-chlorophenyl)-2-oxo-3-butenoic acid was isolated by filtration.

The filtrate was left in the refrigerator overnight, whereby more precipitate is formed, which was filtered off, combined with the first fraction of the salt and washed with diethyl ether. The sodium salt of 4-(4-chlorophenyl)-2-oxo-3-butenoic acid was then treated with a solution of 2N HCI, stirred for some minutes and solid 4-(4- chlorophenyl)-2-oxo-3-butenoic acid was separated via filtration and dried to give 12.7 g of the desired product (70% of theoretical yield).

IR (KBr, cm ¹ ) : 3500-2500, 1719,3, 1686,5, 1603,4, 1587,8, 1081,9. ¹H NMR(CDCI₃, δ) : 7,4 (d, J=8,4Hz, 2H), 7,5 (d, J=16,1Hz, 1 H), 7,6 (d, J=8,4Hz, 2H), 8,^d₁ J=Ie₁IHz₁ IH). a2) 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid

In an alternative route instead of using ethylpyruvate the salt CH₃-C(O)-C(O)-O^" Na⁺ (sodiumpyruvate) was used, dissolved ethanolic water.

b) 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid

4-(4-chlorophenyl)-2-oxo-3-butenoic acid obtained according to step a) (12.6 g, 60 mmoles), 2,4-dichlorophenylhydrazine hydrochloride (12.8 g, 60 mmoles) and glacial acetic acid (200 ml_) were mixed under a nitrogen atmosphere and heated to reflux for 4 hours, cooled down to room temperature (approximately 25 ⁰C) and given into ice-water, whereby a sticky mass was obtained, which was extracted with methylene chloride. The combined methylene chloride fractions were washed with water, dried with sodium sulfate, filtered and evaporated to dryness to give a pale yellow solid (12.7 g, 57% of theoretical yield).

IR (KBr, cm ¹ ) : 3200-2200, 1668,4, 1458, 1251 ,4, 1104,8.

¹H NMR (CDCI₃, δ) : 3,3 (dd, 1H), 3,7 (dd, 1H), 5,9 (dd, 1H), 7,09-7,25 (m, 7H).

The Examples 1 to 6 represent compounds according to formula X. Example 1 :

N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazole-3-carboxamide

(a) 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid chloride

Under nitrogen atmosphere 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro- pyrazole-3-carboxylic acid (2.5 g, 6.8 mmols) obtained according to Example 0 was dissolved in 4 ml_ of in thionyl chloride and heated to reflux for 2.5 hours. The excess thionyl chloride is removed from the reaction mixture under reduced pressure and the resulting crude residue (2.6 g) is used without any further purification.

IR (KBr, CΓTT ,-1 \) ■ : 1732,3, 1700, 1533,3, 1478,1, 1212,9, 826,6.

Starting from this compound compounds according to general formulas I and Il wherein R¹ is a linear or branched d-4-alkyl group can be prepared reacting this compound with the appropriate alkyl alcohol.

(b) N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole- 3-carboxamide

Under nitrogen atmosphere N-aminopiperidine (0.6 mL, 5.6 mmoles) and triethylamine (4 mL) were dissolved in methylene chloride (25 mL). The resulting mixture was ice-cooled down to 0⁰C and a solution of 5-(4-chlorophenyl)-1-(2,4- dichlorophenyO-^δ-dihydro-pyrazole-S-carboxylic acid chloride obtained in step (b) in methylene chloride (15 mL) was added dropwise. The resulting reaction mixture was stirred at room temperature (approximately 25 ⁰C) overnight. Afterwards the reaction mixture was washed with water, followed by a saturated aqueous solution of sodium bicarbonate, then again with water, dried over sodium sulfate, filtered and evaporated to dryness in a rotavapor. The resulting crude solid was crystallized from ethanol. The crystallized solid was removed via filtration and the mother liquors were concentrated to yield a second fraction of crystallized product. The two fractions were combined to give a total amount of 1.7 g (57% of theoretical yield) of N-piperidinyl-5- (4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole-3-carboxamide having a melting point of 183-186°C.

IR (KBr, cm^"1) : 3222,9, 2934,9, 1647,4, 1474,7, 1268,3, 815,6. ¹H NMR ( CDCI₃, δ) : 1,4 (m, 2H), 1,7 (m, 4H), 2,8 (m, 4H), 3,3 (dd, J=6,1 y 18,3Hz, 1H), 3,7 (dd, J=12,5 and 18,3 Hz, 1H), 5,7 (dd, J=6,1 and 12,5 Hz, 1H), 7,0-7,2 (m, 6H)₁ 7,4 (s, 1H).

The compounds according to the following examples 2-6 have been prepared analogously to the process described in Example 1 in combination with Example 0. Example 2:

5-(4^Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid-[1,2,4]triazol-4-yl amide

Melting point: 134-138⁰C.

IR (KBr, cm^"1): 3448, 1686, 1477, 1243, 1091, 821. ¹H NMR(CDCI₃, δ): 3,1 (dd, J=6,2 and 17,9Hz, 1H), 3,7 (dd, J=12,3 and 17,9Hz, 1H), 5,9 (dd, J=6,2 and 12,3 Hz, 1H), 7,2-7,5 (m, 7H), 8,7 (s, 2H), 12,0 (bs, 1H).

Example 3:

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid-(4-methyl-piperazin-1-yl)-amide hydrochloride

Melting point: 150-155⁰C.

IR (KBr, cm ¹) : 3433, 1685, 1477, 1296, 1246, 1088, 1014, 825. ¹H NMR (CDCI₃, δ): 2,7 (d, J=4,2Hz, 3H), 3,0-3,4 (m, 9H), 3,6 (dd, J=11,9 and 17,9 Hz₁ 1H), 5,8 (dd, J=5,5 and 11 ,9 Hz, 1H), 7,1 (d, J=8,4Hz, 2H), 7,25 (2d, J= 8,4 and 8,7 Hz, 3H), 7,4 (d, J=2,2Hz, 1H), 7,5 (d, J=8,7Hz, 1H), 9,8 (s, 1H), 11 ,2 (bs).

Example 4:

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid diethylamide

This compound was obtained in form of an oil.

IR (film, cm^'1) : 2974, 1621, 1471, 1274, 1092, 820.

¹H NMR (CDCI₃, δ): 1,2 (m, 6H), 3,3-3,9 (m, 6H), 5,6 (dd, J=5,8 and 11,7 Hz,

1H), 7-7,25 (m, 7H). Example 5:

[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]- piperidin-1-yl-methanone

Melting point: 105-110⁰C.

IR (KBr₁ cm-¹) : 2934, 1622, 1470, 1446, 1266, 1010, 817. ¹H NMR ( CDCI₃, δ): 1,7 (m, 6H), 3,4 (dd, J=5,7 and 17,9Hz, 1H), 3,7 (m, 3H), 3,9 (m, 2H), 5,6 (dd, J=6,1 y 11,9 Hz, 1H), 7-7,25 (m, 7H).

Example 6:

N-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carbonyl]-4-methyl-phenylsulfonamide

This compound was obtained in form of an amorph solid. IR (KBr, cm ¹) : 1697, 1481 , 1436, 1340, 1169, 1074, 853.

¹H NMR (CDCI₃, δ): 2,4 (s, 3H), 3,2 (dd, J=6,6 and 18,3Hz, 1H), 3,6 (dd, J=12,8 and 18,3Hz, 1H), 5,8 (dd, J=6,6 and 12,8Hz₁ 1H), 7 (d, J=8,2Hz, 2H), 7,2 (s, 1H), 7,3-7,4 (m, 6H), 8 (d, J=8,1Hz, 2H), 9 (s, 1H).

Example 7:

N-oxide of N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5- dihydropyrazole-3-carboxamide

Under nitrogen gas as an inert atmosphere N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4,5-dihydropyrazole-3-carboxamide (0,15 g, 332 mmoles) was dissolved in 7 ml of dichlorom ethane. The resulting solution was ice-cooled to 0 ⁰C and m-chloroperbenzoic acid (0,204 g, 0,83 mmoles) added in several portions. After stirring for 15 minutes a control via thin layer chromatography showed that no starting material was remaining. A saturated solution of sodium bicarbonate was then slowly added, the organic phase separated, washed with water, dried over sodium sulfate and filtered. The filtered solution was evaporated to dryness and the crude product was purified via column chromatography yielding 78 mg (50 % of theoretical yield) of the N-oxide of N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5- dihydropyrazole-3-carboxamide in form of a white solid having a melting point of 115- 120 ⁰C.

IR (KBr, cm ¹): 3202, 1678, 1654, 1474, 1309, 1107.

¹H-NMR (CDCI₃, δ): 1.6 (m, 2H), 1.8-2.0 (m, 4H), 2.55 (m, 2H)₁ 3.3 (dd, J = 6.3 Hz and 18.2 Hz, 1H), 3.7 (m, 3H), 5.8 (dd, J = 6.3 Hz and 12.5 Hz, 1H), 7.0-7.3 (m, 7H)₁ 8.5 (s, 1 H.)

Pharmacological Data/Testing:

The compound according to example 0 is an inhibitor of high blood levels of triglicerides and on the hand other factors like insulin - whose levels are reduced - and which contribute to the metabolic syndrome are also influenced. Decreases of plasma insulin are indicative of an improvement of insulin sensitivity, which is a positive sign for metabolic syndrome as in dietary- induced obese animal models like the one used here basal insulin is raised.

This effect is probed in obese mice fed with high fat diet. In the following paragraphs the method of this study is described.

I. In-vivo testing for lipid parameters or other parameters important for metabolic syndrome (especially of triglycerides) in blood plasma

The study was done using male mice (C57BL76J). Mice were divided in 2 groups:

Group I (vehicle; 0.5% HPMC)

Group Il (Example 0 at 30 mg/kg/day/p.o.)

The animals of both groups were fed with a High Fat Diet.

After 28 days of treatment the animals were sacrificed and blood samples taken. The blood levels of lipid parameters or other parameters important for metabolic syndrome, in this case especially insulin in the plasma of the animals was determined.

The analysis of the whole blood samples was done according to the methods known in the art, and I the case of insulin was done with an ultrasensitive-ELISA-based assay.

Plasma Insulin for the control (Group I) was 285.7 ± 57.9 (pmol/l) and for the Group treated with compound example 0 (Group II) was 156.4 ± 38.6 (pmol/l). This was statistically significant at p<0.05 using ANOVA factorial.

Claims

Claims:

1. Use of a substituted pyrazoline compounds of general formula I₁

wherein

R¹ represents hydrogen or a linear or branched, substituted or unsubstituted, saturated or unsaturated, Ci^-alkyl group,

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched Ci-β-alkyl group, a linear or branched d-e-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched Ci_-6 alkyl,

R⁵ and R⁶ independently of each other represent a linear or branched Ci_-6- alkyl group, a linear or branched Ci-6-alkoxy group, a halogen atom, CH₂F₁ CHF₂, CF₃, CN₁ OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ and -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C1-6 alkyl; R⁷ represents hydrogen, a linear or branched Ci-₆-alkyl group, a linear or branched Ci-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)- NHR¹⁰ and -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched Ci_-6 alky I;

for the manufacture of a medicament for the treatment of metabolic syndrome, especially influencing the blood and lipid parameters- other then triglyceride levels - related to the metabolic syndrome.

2. Use according to claim 1 , characterized in that the compound according to general formula I is selected from compounds according to general formula Ia or Ib or any mixture thereof

3. Use according to any of claims 1 or 2, characterized in that at least one of R², R³ or R⁴ represents hydrogen, while at least one of R², R³ or R⁴ is different from hydrogen.

4. Use according to any one of claims 1, 2 or 3, characterized in that R⁷ represents hydrogen.

5. Use according to any one of claims 1 to 4, characterized in that R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C1-₆- alkyl group, a halogen atom, or CF₃, preferably R², R³ and R⁴ independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF₃.

6. Use according to any one of claims 1 to 5, characterized in that R⁵ and R⁶ independently of each other represent a linear or branched Ci-6-alkyl group, a halogen atom, or CF₃, preferably R⁵ and R⁶ independently of each other represent methyl, ethyl, F, Cl, Br and CF₃.

7. Use according to any one of claims 1 to 6, characterized in that R² represents a chlorine atom in the 4-position of the phenyl ring, while R³ and R⁴ represent hydrogen.

8. Use according to any one of claims 1 to 7, characterized in that R⁵ and R⁶ each represent a chlorine atoms in the 2- and 4-position of the phenyl ring, while R⁷ represents hydrogen.

9. Use according to any one of claims 1 to 8, characterized in that R¹ represents hydrogen, methyl or ethyl, preferably hydrogen.

10. Use according to one or more of claims 1 to 9, characterized in that the compound according to general formula I is selected from a compound of general formula Il

II

wherein

R¹² or R¹³ independently of each other represent a linear or branched Ci-β- alkyl group, a linear or branched Ci-e-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, hydrogen, methyl, ethyl, F, Cl, Br and CF₃,

R¹⁴ or R¹⁵ independently of each other represent a linear or branched Ci-β- alkyl group, a linear or branched Ci-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, methyl, ethyl, F, Cl, Br and CF₃,

11. Use according to claim 10, characterized in that the compound according to general formula Il is selected from compounds according to general formula Ha or Hb or any mixture thereof

Ha lib

12. Use according to any of claims 10 or 11 characterized in that R¹² and R¹³ independently of each other represent hydrogen, a linear or branched C-i-β- alkyl group, a halogen atom, or CF₃, preferably R¹² and R¹³ independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF₃.

13. Use according to any one of claims 10, 11 or 12, characterized in that R¹⁴, and R¹⁵ independently of each other represent a linear or branched d-β-alkyl group, a halogen atom, or CF₃, preferably R¹⁴ and R¹⁵ independently of each other represent methyl, ethyl, F, Cl, Br and CF₃.

14. Use according to any one of claimsiO to 13, characterized in that R¹³ represents Cl and R¹² represents hydrogen.

15. Use according to any one of claims 10 to 14, characterized in that R¹⁴ and R¹⁵ each represent Cl.

16. Use according to any one of claims 10 to 15, characterized in that R¹ represents hydrogen, methyl or ethyl, preferably hydrogen.

17. Use according to one or more of claims 1 to 14 selected from the group consisting of:

• (rac)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1 H-pyrazol-

3-carboxylic acid,

• (R)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4.5-cliⁿyclro-1H-pyrazol- 3-carboxylic acid,

• (S)-5-(4-chloro-phenyl)-1 -(2,4-dichlorophenyl)-4,5-dihydro-1 H-pyrazol- 3-carboxylic acid,

or any mixture thereof

18. Use according to any of claims 1 to 17 characterized in that in addition to at least one compound according to either of general formulas I, Ia, Ib, II, Ua and/or lib at least one substituted pyrazoline compound according to general formula X is being used,

wherein

R¹⁶ represents an optionally at least mono-substituted phenyl group,

R¹⁷ represents an optionally at least mono-substituted phenyl group,

NR¹⁹R²⁰-moiety,

R¹⁹ and R²⁰, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group, an -SO₂-R²¹-moiety, or an - NR²²R²³-moiety, with the proviso that R¹⁹ and R²⁰ do not identically represent hydrogen, ' R²¹ represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a linear or branched alkylene group,

19. Use according to claim 18, characterized in that in the compound according to general formula X R¹⁶ represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched Ci-β-alkyl group, a linear or branched Ci-₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R', SH, SR', SOR', SO₂R', NH₂, NHR', NR¹R", -(C=O)-NH₂, -(C=O)-NHR' and -(C=O)-NR¹R" whereby R' and R" for each substituent independently represent linear or branched d-β alkyl, preferably R¹⁶ represents a phenyl group, which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF₃, more preferably R¹⁶ represents a phenyl group, which is mono-substituted with a chlorine atom in the 4-position.

20. Use according to any of claims 18 or 19, characterized in that in the compound according to general formula X R¹⁷ represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a linear or branched Ci-₆-alkyl group, a linear or branched C-i-β-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R', SH, SR', SOR', SO₂R', NH₂, NHR', NR¹R", -(C=O)-NH₂, -(C=O)-NHR' and -(C=O)-NR¹R", whereby R^* and optionally R" for each substituent independently represent linear or branched Ci- ₆ alkyl, preferably R¹⁷ represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF₃, more preferably R¹⁷ represents a phenyl group, which is di- substituted with two chlorine atoms in its 2- and 4-position.

21. Use according to any of claims 18 to 20, characterized in that in the compound according to general formula X R¹⁸ represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C₃-β cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an -NR¹⁹R²°-moiety, preferably R¹⁸ represents a saturated, optionally at least mono-substituted, optionally one or more nitrogen-atoms as ring member containing C_3-S cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an -NR¹⁹R²⁰-moiety, more preferably R¹⁸ represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, whereby each of these groups may be substituted with one or more C_1-6-alkyl groups, or an -NR¹⁸R¹⁹-moiety.

22. Use according to any of claims 18 to 21, characterized in that in the compound according to general formula X R¹⁹ and R²⁰, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci-₆-aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C₃-8-cycloaliphatic group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, or an optionally at least mono- substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene (-CH2-) or ethylene (-CH₂-CH2)-group, an -Sθ2-R²¹-moiety, or an -NR²²R²³-moiety, preferably one of these residues R¹⁹ and R²⁰ represents a hydrogen atom and the other one of these residues R¹⁹ and R²⁰ represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C₃-₈-cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, an -Sθ2-R²¹-moiety, or an -NR²²R²³- moiety, or R¹⁹ and R²⁰, identical or different, each represent a C1-₆ alkyl group, more preferably one of these residues R¹⁹ and R²⁰ represents a hydrogen atom and the other one of these residues R¹⁹ and R²⁰ represents an optionally at least mono- substituted pyrrolidinyl group, an optionally at least mono-substituted piperidinyl group, an optionally at least mono-substituted piperazinyl group, an optionally at least mono-substituted triazolyl group, an -S0₂-R²¹-moiety, or an -NR²²R²³-moiety, or R¹⁹ and R²⁰, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tert.-butyl group.

23. Use according to any of claims 18 to 22, characterized in that in the compound according to general formula X R²¹ represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C-ι-6 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C_3-8 cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or bonded via a methylene (-CH₂-) or ethylene (-CH₂- CH₂)-group, preferably R²¹ represents a Ci-6-alkyl group, a saturated, optionally at least mono-substituted cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or a phenyl group, which is optionally substituted with one or more d-β alkyl groups.

24. Use according to any of claims 18 to 23, characterized in that in the compound according to general formula X R²² and R²³, identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted Ci_-6 aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-₈ cycloaliphatic group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, or an optionally at least mono- substituted, 5- or 6 membered aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system and/or bonded via a methylene (-CH₂-) or ethylene (-CH₂-CH2)-group₁ preferably R²² and R²³, identical or different, represent a hydrogen atom or a Ci_-6 alkyl radical.

25. Use according to any of claims 18 to 24, characterized in that the compound according to general formula X is represented by a structure wherein

R¹⁹ represents a hydrogen atom or a linear or branched

group,

R²⁰ represents a linear or branched Ci_-6 alkyl group, an -SO₂-R²¹-moiety, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, whereby each of the heterocyclic rings may be substituted with one or more, identical or different, Ci-₆-alkyl groups, and R²¹ represents a phenyl group, which is optionally substituted with one or more Ci-β alkyl groups, which may be identical or different,

26. Use according to any of claims 18 to 25, characterized in that at least one compound according to formula X is selected from the group consisting of:

N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4₎5-dihydro-1H- pyrazol-3-carboxamide,

(rac)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazol-3-carboxam ide,

(S)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazol-3-carboxam ide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid-[1 ,2,4]-triazole-4~yl-amide,

5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3- carboxylic acid diethylamide, [5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4,5-dihydro-1H-pyrazole-3-yl]- piperidine-1-yl-methanone,

N-[5-(4-Chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3- carbonyl]-4-m ethyl phenyl sulfonamide,

27. Use according to any of claims 18 to 26, characterized in that at least the following compounds are used:

• (rac)-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4₎5-dihydro-1H-pyrazol- 3-carboxylic acid,

• (^^-(Φchloro-phenyO-i^.^dichlorophenyl^.δ-dihydro-IH-pyrazol- 3-carboxylic acid,

or any mixture thereof

and

• N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H- pyrazol-3-carboxamide;

• (rac)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5- dihydro-1 H-pyrazol-3-carboxamide; • (R)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2_>4-dichlorophenyl)-4_I5-dihyclro- 1 H-pyrazol-3-carboxamide;

• (S)-N-piperidinyl-5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro- 1 H-pyrazol-3-carboxamide; or any mixture thereof